DTIL
Price
$6.78
Change
+$0.07 (+1.04%)
Updated
Oct 22 closing price
Capitalization
187.14M
11 days until earnings call
Intraday BUY SELL Signals
ORMP
Price
$4.12
Change
-$0.02 (-0.48%)
Updated
Oct 22 closing price
Capitalization
171.38M
21 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

DTIL vs ORMP

DTIL vs ORMP Comparison Chart in %
View a ticker or compare two or three
VS
DTIL vs. ORMP commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DTIL is a StrongBuy and ORMP is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for DTIL with price predictions
Oct 22, 2026

DTIL's RSI Oscillator climbs out of oversold territory

The RSI Oscillator for DTIL moved out of oversold territory on September 22, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 41 similar instances when the indicator left oversold territory. In 33 of the 41 cases the stock moved higher. This puts the odds of a move higher at 80%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on DTIL as a result. In 66 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.

The Moving Average Convergence Divergence (MACD) for DTIL just turned positive on October 19, 2026. Looking at past instances where DTIL's MACD turned positive, the stock continued to rise in 35 of 45 cases over the following month. The odds of a continued upward trend are 78%.

Following a +3.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where DTIL advanced for three days, in 189 of 243 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.

DTIL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where DTIL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

The Aroon Indicator for DTIL entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 30 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 32 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.132) is normal, around the industry mean (2.973). P/E Ratio (-5.424) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (2.997) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. DTIL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DTIL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for ORMP with price predictions
Oct 22, 2026

ORMP's Indicator enters downward trend

The Aroon Indicator for ORMP entered a downward trend on October 14, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 186 similar instances where the Aroon Indicator formed such a pattern. In 157 of the 186 cases the stock moved lower. This puts the odds of a downward move at 84%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ORMP as a result. In 72 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.

ORMP moved below its 50-day moving average on October 01, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for ORMP crossed bearishly below the 50-day moving average on October 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 65%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ORMP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ORMP's RSI Oscillator exited the oversold zone, 25 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 46 of 62 cases where ORMP's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.

Following a +1.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where ORMP advanced for three days, in 216 of 263 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

ORMP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 15 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. ORMP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 69 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.540) is normal, around the industry mean (2.973). P/E Ratio (0.972) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.243) settles around the average of (128.121) among similar stocks. P/S Ratio (90.909) is also within normal values, averaging (438.009).

The Tickeron PE Growth Rating for this company is 93 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ORMP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
DTIL vs ORMP: Fundamental Ratings
DTIL
ORMP
OUTLOOK RATING
1..100
1758
VALUATION
overvalued / fair valued / undervalued
1..100
32
Undervalued
69
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9915
PRICE GROWTH RATING
1..100
5744
P/E GROWTH RATING
1..100
3093
SEASONALITY SCORE
1..100
9050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

DTIL's Valuation (32) in the Biotechnology industry is somewhat better than the same rating for ORMP (69) in the Pharmaceuticals Other industry. This means that DTIL’s stock grew somewhat faster than ORMP’s over the last 12 months.

DTIL's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ORMP (100) in the Pharmaceuticals Other industry. This means that DTIL’s stock grew similarly to ORMP’s over the last 12 months.

ORMP's SMR Rating (15) in the Pharmaceuticals Other industry is significantly better than the same rating for DTIL (99) in the Biotechnology industry. This means that ORMP’s stock grew significantly faster than DTIL’s over the last 12 months.

ORMP's Price Growth Rating (44) in the Pharmaceuticals Other industry is in the same range as DTIL (57) in the Biotechnology industry. This means that ORMP’s stock grew similarly to DTIL’s over the last 12 months.

DTIL's P/E Growth Rating (30) in the Biotechnology industry is somewhat better than the same rating for ORMP (93) in the Pharmaceuticals Other industry. This means that DTIL’s stock grew somewhat faster than ORMP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DTILORMP
RSI
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
83%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
74%
Momentum
ODDS (%)
Bullish Trend 1 day ago
78%
Bearish Trend 1 day ago
80%
MACD
ODDS (%)
Bullish Trend 1 day ago
78%
N/A
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
76%
Bearish Trend 1 day ago
80%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
81%
Advances
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 18 days ago
82%
Declines
ODDS (%)
Bearish Trend 9 days ago
86%
Bearish Trend 1 day ago
81%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
84%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (DTIL: $6.78 vs. ORMP: $4.12)
Brand notoriety: DTIL and ORMP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DTIL: 49% vs. ORMP: 57%
Market capitalization -- DTIL: $187.14M vs. ORMP: $171.38M
DTIL [@Biotechnology] is valued at $187.14M. ORMP’s [@Biotechnology] market capitalization is $171.38M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The average market capitalization across the [@Biotechnology] industry is $2.14B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DTIL’s FA Score shows that 2 FA rating(s) are green while ORMP’s FA Score has 1 green FA rating(s).

  • DTIL’s FA Score: 2 green, 3 red.
  • ORMP’s FA Score: 1 green, 4 red.
According to our system of comparison, DTIL is a better buy in the long-term than ORMP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DTIL’s TA Score shows that 5 TA indicator(s) are bullish while ORMP’s TA Score has 4 bullish TA indicator(s).

  • DTIL’s TA Score: 5 bullish, 3 bearish.
  • ORMP’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, DTIL is a better buy in the short-term than ORMP.

Price Growth

DTIL (@Biotechnology) experienced а +9.89% price change this week, while ORMP (@Biotechnology) price change was -1.44% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.17%. For the same industry, the average monthly price growth was -18.21%, and the average quarterly price growth was -15.24%.

Reported Earning Dates

DTIL is expected to report earnings on Nov 02, 2026.

ORMP is expected to report earnings on Nov 12, 2026.

Industries' Descriptions

@Biotechnology (-1.17% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
DTIL
Daily Signal:
Gain/Loss:
ORMP
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

ORMP and

Correlation & Price change

A.I.dvisor indicates that over the last year, ORMP has been loosely correlated with DRTS. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if ORMP jumps, then DRTS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ORMP
1D Price
Change %
ORMP100%
-0.48%
DRTS - ORMP
53%
Loosely correlated
-4.30%
INO - ORMP
44%
Loosely correlated
+5.48%
MBIO - ORMP
44%
Loosely correlated
-2.84%
CGEM - ORMP
42%
Loosely correlated
+0.20%
CGEN - ORMP
41%
Loosely correlated
-7.55%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
NNY7.850.05
+0.64%
Nuveen New York Municipal Value Fund
IIM11.300.05
+0.44%
INVESCO VALUE Municipal Income TRUST
STEN28.43-0.27
-0.94%
iShares Large Cap 10% Target Buffer Sep ETF (STEN)
XT82.38-1.15
-1.38%
iShares Future Exponential Technologies ETF (XT)
ISBG13.75-1.09
-7.38%
Incomestkd 1X Bitcoin & 1X Gold Premium ETF